Revolution Medicines (RVMD) Profit After Tax (2019 - 2026)

Revolution Medicines' Profit After Tax history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 112.64% year-over-year to -$453.8 million in Q1 2026; TTM through Mar 2026 was -$1.4 billion, a 96.38% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 billion, down 88.2% from the prior year.
• Profit After Tax retreated to -$453.8 million in Q1 2026 per RVMD's latest filing, from -$363.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$56.5 million in Q4 2022 and bottomed at -$453.8 million in Q1 2026.
• The 5-year median for Profit After Tax is -$133.2 million (2024), against an average of -$168.6 million.
• Across the five-year window, Profit After Tax fell 6.28% in 2022 and slumped 181.76% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$56.5 million in 2022, then slumped by 181.76% to -$159.2 million in 2023, then retreated by 22.21% to -$194.6 million in 2024, then plunged by 86.55% to -$363.0 million in 2025, then decreased by 25.03% to -$453.8 million in 2026.
• Per Business Quant, the three latest RVMD Profit After Tax figures stand at -$453.8 million (Q1 2026), -$363.0 million (Q4 2025), and -$305.2 million (Q3 2025).